Answers are grounded in this paper and cite their sources.
// Alfredo Perales-Puchalt 1 , Elizabeth K. Duperret 1 , Kar Muthumani 1 and David B. Weiner 1 1 Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA Correspondence to: David B. Weiner, email: weiner@Wistar.org Keywords : immunotherapy; cancer; immune checkpoints; DMAb; monoclonal antibody Received: December 13, 2018 Accepted: December 16, 2018 Published: January 01, 2019 Abstract Checkpoint inhibitors (CPI) have revolutionized the treatment of many solid tumors. However, difficulties in production, stability, the requirement of frequent high doses for antibody administration and long intravenous administration are recurring issues. Synthetically designed DNA-encoded monoclonal antibodies (DMAbs) are a novel delivery method for antibody therapy which could potentially address many of these issues, simplifying design and implementation of MAb-based therapies. DMAbs delivered through plasmid DNA injection and electroporation have been used in preclinical models for the treatment or prophylaxis of infectious diseases, cancer and cardiovascular disease. Our group has recently reported that immune checkpoint blockers can be optimized and delivered in vivo advancing further DMAb technology by optimization, expression and in vivo functional characterization of anti-CTLA4 antibodies. Here we report optimization, expression and binding of DMAbs based on anti-PD1 CPI and discuss the potential of DMAbs in checkpoint immunotherapy.
No takes yet. Share an insight, caveat, or question.
Perales‐Puchalt et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: